Baicalein for ALS

Also known as: 5,6,7-Trihydroxyflavone, Scutellaria baicalensis extract

Baicalein's lipoxygenase inhibition and Nrf2 activation address neuroinflammation and oxidative stress in ALS.

Mechanism of Action

Baicalein inhibits 12/15-lipoxygenase, reducing pro-inflammatory lipid mediators in ALS spinal cord. It activates Nrf2 for motor neuron antioxidant defense and inhibits iron-dependent lipid peroxidation (ferroptosis) in motor neurons.

General mechanism: Flavone from Scutellaria. 12/15-LOX inhibitor, α-synuclein aggregation inhibitor, ferroptosis modulator, Nrf2 activator.

Current Evidence

Preclinical neuroprotection data. Anti-ferroptotic effects may be relevant to ALS motor neuron death. No ALS trials.

Clinical Status: Preclinical. Anti-ferroptotic mechanism emerging.

Safety Profile

Safe. Traditional medicine use. GI effects possible. May interact with iron metabolism at high doses.

Key Research Questions

View glossary entry →

← Back to ALS Research